<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03125616</url>
  </required_header>
  <id_info>
    <org_study_id>16.0247</org_study_id>
    <secondary_id>2017-001487-38</secondary_id>
    <nct_id>NCT03125616</nct_id>
  </id_info>
  <brief_title>Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B</brief_title>
  <acronym>BEAR Men B</acronym>
  <official_title>Babies Born Early Antibody Response to Men B Vaccination: A Phase IV Multicentre Randomised Study to Evaluate the Primary and Booster Immune Responses in UK Preterm Infants Receiving Routine Immunisations and Incorporating a Three Dose Versus a Two Dose Schedule of 4CMenB (Bexsero®) for Primary Immunisation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St George's, University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>MeningitisNow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Public Health England</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St George's, University of London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the UK, babies receive their vaccinations according to a standard schedule, irrespective&#xD;
      of their gestation at birth. This policy is designed so that all babies are protected as&#xD;
      early as possible from vaccine preventable diseases such as polio, diphtheria, tetanus,&#xD;
      rotavirus, pertussis (whooping cough), Haemophilus influenzae type B, pneumococcal disease&#xD;
      and now meningococcal B disease. The 4CMenB vaccination (Bexsero®) was added to the UK&#xD;
      schedule in September 2015 and there has been no research looking at whether the vaccine&#xD;
      gives the same protection to babies born early as it does to those born at term. The&#xD;
      Investigators want to compare two different schedules of 4CMenB and see if one gives better&#xD;
      protection to babies born prematurely. It is possible that an extra 4CMenB dose (i.e. three&#xD;
      doses in early infancy instead of two) will offer better protection for premature babies.&#xD;
      This is what the Investigators are trying to find out through this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open label, phase IV study. After appropriate consent, 132 premature infants&#xD;
      born at &lt;35 weeks gestation (i.e. up to 34 weeks and 6 days), 50% &lt;30 weeks gestation (i.e.&#xD;
      up to 29 weeks and 6 days) will be randomised to 1 of 2 4CMen B schedules either at 2,4 and&#xD;
      12 months or 2,3,4 and 12 months. Babies will remain in the study for around 12 months, from&#xD;
      recruitment to 13 months of age. All visits can be performed at the participant's home or in&#xD;
      clinic, depending on the preference of the parents and study team.&#xD;
&#xD;
      Blood samples will be obtained at 5 months of age (post primary sample), 12 months&#xD;
      (persistence sample) and 13 months (post booster sample). Reactogenicity and safety will be&#xD;
      assessed by caregiver completion of a 7-day diary after each vaccine dose. Inpatients will be&#xD;
      monitored for cardiorespiratory events for 72 hours after vaccination by healthcare staff and&#xD;
      this information will be collected on the CRF. This will include details of oxygen&#xD;
      saturations, heart rate, respiratory rate and details of any episodes of desaturation,&#xD;
      bradycardia or apnoea. Particular emphasis will be placed on rates, timing and intensity of&#xD;
      fever and other adverse reactions in the first 24 hours after vaccination, because this&#xD;
      remains a cause of great concern amongst neonatologists.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">August 28, 2020</completion_date>
  <primary_completion_date type="Actual">September 2, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be an open label, phase IV study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hSBA GMT</measure>
    <time_frame>Tested in each infant at 5 months of age (1 month after completion of primary vaccinations)</time_frame>
    <description>hSBA GMT one month after completing primary immunisations for relevant 4CMenB (Bexsero®) antigens: fHbp, NadA and PorA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hSBA proportions</measure>
    <time_frame>Tested in each infant at 5 months of age (1 month after completion of primary vaccinations)</time_frame>
    <description>hSBA proportions ≥ 1:4, one month after completing primary immunisations for relevant 4CMenB (Bexsero®) antigens: fHbp, NadA and PorA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reactions within 7 days</measure>
    <time_frame>Assessed in each infant for the 7 days following vaccination</time_frame>
    <description>The percentage of infants experiencing fever, local reactions and non-febrile systemic reactions within the 7 days following each vaccine dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiorespiratory status for 72 hours following vaccination</measure>
    <time_frame>Assessed in all infants in hospital for 72 hours following vaccination</time_frame>
    <description>The percentage of inpatients experiencing change / deterioration in cardiorespiratory status within the 72 hours following each vaccine dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suspicion of sepsis in 7 days following vaccination</measure>
    <time_frame>Assessed in all infants in the 7 days following vaccination</time_frame>
    <description>The percentage of infants investigated for sepsis and commenced on antibiotics within 7 days of vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever and/or suspicion of sepsis in the 28 days following vaccination</measure>
    <time_frame>Assessed in all infants in the 28 days following vaccination</time_frame>
    <description>The percentage of infants who experience fever and/or are investigated for sepsis and commenced on antibiotics within 28 days of vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>Assessed in all infants at the conclusion of the study</time_frame>
    <description>The percentage of infants who experience a serious adverse event at any point within the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of hSBA GMTs</measure>
    <time_frame>Assessed in all infants at 12 months of age</time_frame>
    <description>hSBA GMTs at 12 months of age (pre booster) for relevant 4CMenB (Bexsero®) antigens: fHbp, NadA and PorA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of hSBA proportions ≥1:4</measure>
    <time_frame>Assessed in all infants at 12 months of age</time_frame>
    <description>hSBA proportions ≥1:4, at 12 months of age (pre booster) for relevant 4CMenB (Bexsero®) antigens: fHbp, NadA and PorA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Booster response: hSBA GMTs</measure>
    <time_frame>Assessed in all infants at 13 months of age</time_frame>
    <description>hSBA GMTs at 13 months of age (post booster) for relevant 4CMenB (Bexsero®) antigens: fHbp, NadA and PorA;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Booster response: hSBA proportions ≥1:4</measure>
    <time_frame>Assessed in all infants at 13 months of age</time_frame>
    <description>hSBA proportions ≥1:4, at 13 months of age (post booster) for relevant 4CMenB (Bexsero®) antigens: fHbp, NadA and PorA.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Prematurity</condition>
  <condition>Vaccination</condition>
  <condition>Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>Standard UK 4CMenB vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4CMenB (Bexsero®) vaccination at 2 and 4 months and a booster at 12 months .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Additional 4CMenB Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4CMenB (Bexsero®) vaccination at 2, 3 and 4 months and a booster at 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4CMenB Vaccine</intervention_name>
    <description>The infants will receive an intramuscular injection of the 4CMenB vaccine at 2 months</description>
    <arm_group_label>Additional 4CMenB Vaccine</arm_group_label>
    <arm_group_label>Standard UK 4CMenB vaccine</arm_group_label>
    <other_name>Bexsero</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4CMenB Vaccine</intervention_name>
    <description>The infants will receive an intramuscular injection of the 4CMenB vaccine at 3 months</description>
    <arm_group_label>Additional 4CMenB Vaccine</arm_group_label>
    <other_name>Bexsero</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4CMenB Vaccine</intervention_name>
    <description>The infants will receive an intramuscular injection of the 4CMenB vaccine at 4 months</description>
    <arm_group_label>Additional 4CMenB Vaccine</arm_group_label>
    <arm_group_label>Standard UK 4CMenB vaccine</arm_group_label>
    <other_name>Bexsero</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4CMenB Vaccine</intervention_name>
    <description>The infants will receive an intramuscular injection of the 4CMenB vaccine at 12 months</description>
    <arm_group_label>Additional 4CMenB Vaccine</arm_group_label>
    <arm_group_label>Standard UK 4CMenB vaccine</arm_group_label>
    <other_name>Bexsero</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Premature infant born at &lt;35 weeks gestation&#xD;
&#xD;
          -  No contraindications to vaccination according to the 'Green Book'&#xD;
&#xD;
          -  Willing and able to comply with study procedures&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to vaccination according to the Green Book&#xD;
&#xD;
          -  Life-limiting congenital abnormality or condition&#xD;
&#xD;
          -  Prior diagnosis of an immunodeficiency syndrome&#xD;
&#xD;
          -  Considered unlikely to complete expected follow up until the end of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Weeks</minimum_age>
    <maximum_age>11 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Heath, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>St George's, University of London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Georges University Hospital NHS Foundation Trust</name>
      <address>
        <city>Tooting</city>
        <state>London</state>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.gov.uk/government/publications/meningococcal-the-green-book-chapter-22</url>
    <description>Meningococcal: the green book, chapter 22</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 19, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prematurity</keyword>
  <keyword>Vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

